676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797629446374555648 |
|---|---|
| author | Elizabeth Evans Nagashree Seetharamu Crystal Mallow Maurice Zauderer Barbara Burtness Marya Chaney Alexander Spira Conor Steuer Tarek Mekhail J Thaddeus Beck Douglas Adkins Terrence Fisher Amber Foster John Leonard Nabil F Saba Megan Baumgart Steven Hager Christopher Chay |
| author_facet | Elizabeth Evans Nagashree Seetharamu Crystal Mallow Maurice Zauderer Barbara Burtness Marya Chaney Alexander Spira Conor Steuer Tarek Mekhail J Thaddeus Beck Douglas Adkins Terrence Fisher Amber Foster John Leonard Nabil F Saba Megan Baumgart Steven Hager Christopher Chay |
| author_sort | Elizabeth Evans |
| collection | DOAJ |
| first_indexed | 2024-03-11T10:54:25Z |
| format | Article |
| id | doaj.art-b0d9d82d46d944f0bc9f5f99a3a31fd0 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T10:54:25Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-b0d9d82d46d944f0bc9f5f99a3a31fd02023-11-13T12:00:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0676676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)Elizabeth Evans0Nagashree Seetharamu1Crystal Mallow2Maurice Zauderer3Barbara Burtness4Marya Chaney5Alexander Spira6Conor Steuer7Tarek Mekhail8J Thaddeus Beck9Douglas Adkins10Terrence Fisher11Amber Foster12John Leonard13Nabil F Saba14Megan Baumgart15Steven Hager16Christopher Chay171Vaccinex, Rochester, NY, USA2Northwell Health, Lake Success, NY, USAAff42 grid.422076.5Vaccinex Rochester NY USA3Vaccinex Inc., Rochester, NY, USAAff8 grid.47100.320000000419368710Yale University School of Medicine New Haven CT USA20Merck and Co., Inc, Kenilworth, NJ, USADepartment of Medical Oncology, Virginia Cancer Specialists, Fairfax, Virginia, USA8Winship Cancer Institute of Emory University, Atlanta, GA, USAThe Cleveland Clinic, Cleveland, Ohio, USA7Highlands Oncology, Springdale, AR, USAWashington University School of Medicine, St. Louis, MO, USA1Vaccinex, Rochester, NY, USA1Vaccinex, Rochester, NY, USA1Vaccinex, Rochester, NY, USADepartment of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA10University of Rochester, Rochester, NY, USA11California Cancer Associates for Research and Excellence, Inc, Fresno, CA, USA12Messino Cancer Centers, Ashville, NC, USA |
| spellingShingle | Elizabeth Evans Nagashree Seetharamu Crystal Mallow Maurice Zauderer Barbara Burtness Marya Chaney Alexander Spira Conor Steuer Tarek Mekhail J Thaddeus Beck Douglas Adkins Terrence Fisher Amber Foster John Leonard Nabil F Saba Megan Baumgart Steven Hager Christopher Chay 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84) Journal for ImmunoTherapy of Cancer |
| title | 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84) |
| title_full | 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84) |
| title_fullStr | 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84) |
| title_full_unstemmed | 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84) |
| title_short | 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84) |
| title_sort | 676 pepinemab a semaphorin 4d inhibitor in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b 2 study for first line treatment of r m hnscc keynote b84 |
| work_keys_str_mv | AT elizabethevans 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT nagashreeseetharamu 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT crystalmallow 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT mauricezauderer 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT barbaraburtness 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT maryachaney 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT alexanderspira 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT conorsteuer 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT tarekmekhail 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT jthaddeusbeck 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT douglasadkins 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT terrencefisher 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT amberfoster 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT johnleonard 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT nabilfsaba 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT meganbaumgart 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT stevenhager 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 AT christopherchay 676pepinemabasemaphorin4dinhibitorincombinationwithpembrolizumabinducedformationoforganizedlymphoidaggregatesinphase1b2studyforfirstlinetreatmentofrmhnscckeynoteb84 |